Form 4: Envoy Medical Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Chas McKhann was granted 100,000 stock options in Envoy Medical, Inc. as part of a long-term incentive plan.
Summary
- Director Chas McKhann received a grant of 100,000 stock options for Class A Common Stock.
- The options have an exercise price of $0.72 per share.
- The grant date is April 15, 2026, with an expiration date of April 15, 2036.
- Vesting begins on May 15, 2026, and occurs pro rata on the 15th of each month over a 36-month period.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
- Vesting schedule encourages long-term retention of the director.
Negatives
- Grant results in potential future dilution for existing shareholders upon exercise.
Risks
- Market price volatility could impact the value of the options and the incentive alignment.
- The exercise price of $0.72 is subject to market fluctuations.
Future Outlook
The options vest over a three-year period starting May 2026, indicating a long-term commitment to the company's equity performance.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to ensure leadership remains focused on long-term growth and shareholder alignment within the medical device sector.
Comparison to Industry Standards
- The use of multi-year pro-rata vesting is consistent with standard executive and director compensation packages in the U.S. healthcare technology sector.
- The 10-year term for options is a standard industry practice for equity incentive plans.
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options to commence on May 15, 2026.
Key Dates
| Date | Description |
|---|---|
| 04/15/2026 | Transaction date of the stock option grant. |
| 04/17/2026 | Date of filing. |
| 05/15/2026 | Commencement of the 36-month vesting period. |
| 04/15/2036 | Expiration date of the stock options. |
Keywords
Envoy Medical, COCH, Form 4, Stock Options, Insider Trading, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.